Yibo Yin

Parker Institute for Cancer Immunotherapy

MedicineImmunology and MicrobiologyEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms”.

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

Frontiers in Oncology(2021)10.3389/fonc.2021.664236

N/A

0DataRank · unranked

37 citations

Zev A. Binder, Yibo Yin, Logan Zhang, Jiasi Vicky Zhang, Daniel Y. Zhang +5 more

High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.02.04.429797

N/A

0DataRank · unranked

4 citations

Zev A. Binder, Yibo Yin, Logan Zhang, Jiasi Vicky Zhang, Daniel Y. Zhang +5 more

Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM

Frontiers in Immunology(2025)10.3389/fimmu.2025.1579925

N/A

0DataRank · unranked

2 citations

Alina C. Boesteanu, Yibo Yin, Reiss Reid, Laura Roccograndi, Nadia Dahmane +5 more